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Abstract 
Alzheimer’s disease (AD) is the most common age-related neurodegenerative disorder. 
Despite this, there are no drugs for preventing the onset of AD. Preclinical studies suggest that 
interaction between amyloid-β peptides (Aβ) and the α7 nicotinic acetylcholine receptor (α7 
nAChR) plays a key role in AD pathology, and that α7 nAChR agonists could act as potential 
therapeutic drugs for AD. A recent study demonstrated that tropisetron, a potent α7 nAChR 
agonist and serotonin 5-HT3 receptor antagonist, also bound to the ectodomain of amyloid 
precursor protein (APP). Furthermore, tropisetron promoted greater improvements in memory 
than current AD therapeutic drugs, such as memantine and donepezil. Positron emission 
tomography studies detected Aβ deposition and inflammation in the brains of subjects with 
amnestic mild cognitive impairment (MCI) before the onset of AD. Given the role of α7 
nAChR in Aβ deposition and inflammation, tropisetron represents an attractive potential 
therapeutic drug to delay or prevent MCI and AD. Additionally since this drug is used 
internationally to treat chemotherapy-induced emesis, its safety record is already known. 
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1. Introduction 
The World Alzheimer Report 2013 (1) estimated that between 2010 and 2050, the worldwide 
numbers of older people needing care will nearly treble, from 101 to 277 million. Nearly half 
of these older people are likely to be living with and experiencing the effects of dementia. 
Furthermore, costs will increase in line with the number of older people suffering dementia. 
The World Alzheimer Report predicted a near doubling in worldwide societal costs from 
US$604 billion in 2010 to US$1,117 billion, by 2030 (1).   
Alzheimer’s disease (AD) is the most common age-related neurodegenerative disorder, 
and AD is the most common cause of dementia. It is a slowly progressing disease 
characterized by three stages – an early preclinical stage with no symptoms, a middle stage 
with mild cognitive impairment (MCI) and a final stage with dementia (Figure 1). Currently, 
there are no therapeutic agents for preventing the onset of MCI or AD. A decade of 
disappointing clinical trials testing agents aimed at modifying AD disease in patients, suggest 
that effective treatment should be targeted at earlier stages of the disease, that is, even before 
overt symptoms arise (2).  
2. Role of Aβ - α7 nAChR interaction in AD pathology 
Although the precise mechanisms underlying AD pathology are currently unknown, the 
accumulation and aggregation of amyloid-β (Aβ) peptides in brain regions, such as the 
hippocampus and cerebral cortex, are believed to be an early event in the pathogenesis of this 
disease. Another prominent feature of AD pathology is the loss of cholinergic neurons and 
nicotinic acetylcholine receptors (nAChRs) throughout the brain (Figure 1) (3, 4). However, 
the mechanisms linking Aβ to the loss of cholinergic neurons and nAChRs remain to be fully 
elucidated. The α7 subtype of nAChRs, a major subtype of nAChRs in the brain, is a 
functional homopentameric receptor since ACh-gated ion channels open when five identical 
α7-subunits assemble together (4). The α7 nAChRs are located presynaptically, including on 
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cholinergic projection pathways from the basal forebrain, where they are active in the 
Ca2+-dependent release of neurotransmitters. Additionally, α7 nAChRs are localized 
postsynaptically on γ-aminobutyric acid-ergic inhibitory interneurons, particularly in the 
hippocampus and cerebral cortex (4). Accumulating evidence suggests that the α7 nAChR is 
integral to the pathogenesis of AD, and therefore that α7 nAChR agonists could be potential 
therapeutic drugs for MCI and AD (3, 4). Despite the presence of high amounts of amyloid 
precursor protein (APP) and Aβ deposits in the brain, deleting α7 nAChR subunits in the 
mouse model of AD protects against dysfunction of synaptic integrity (pathology and 
plasticity) and cognitive function (5). Furthermore, chronic administration of nicotine 
prevented Aβ-induced reductions of α7 nAChR in an animal model of AD (6). Although the 
mechanism underlying the neuroprotective effect of nicotine is unclear, it is likely that 
nicotine protects cells against Aβ toxicity by upregulation of α7 nAChR (6). Subsequently, S 
24795, a partial agonist at α7 nAChR, was found to reduce Aβ42 - α7 nAChR interaction and 
Aβ42-inducedτphosphorylation (7). Taken together, disrupting the Aβ - α7 nAChR 
interaction may represent a novel approach to reducing Aβ-mediated functional deficits, 
neurodegeneration, and possibly the neuropathological features of AD. 
3. Tropisetron  
Tropisetron (NavobanⓇ), a 5-hydroxytryptamine (5-HT)3 receptor antagonist, is widely used 
to treat chemotherapy-induced emesis outside of the United States (U.S.). In addition to its 
5-HT3 receptor antagonism properties, tropisetron is also a partial agonist at the α7 nAChR. 
Tropisetron (5-20 mg/day) is reportedly effective in the treatment of auditory sensory gating 
P50 deficits, cognitive impairment, and negative symptoms in patients with schizophrenia 
(8-11), indicating that tropisetron would be a potential therapeutic drug for schizophrenia (3, 
12).  
Using a clinical compound library, Spilman et al. (13) recently identified tropisetron as 
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an agent that consistently increased soluble amyloid precursor protein α (sAPPα), which acts 
as a trophic factor (Figure 2). A subsequent assay showed that tropisetron consistently 
increased the sAPPα/Aβ1-42 ratio, suggestive of a beneficial effect in ameliorating the AD 
phenotype. In vivo studies using J20 mice (an animal model of AD), showed that tropisetron 
(0.5 mg/kg/day) improved the sAPPα/Aβ ratio, along with spatial and working memory in 
mice, and that tropisetron was effective both during the symptomatic, pre-plaque phase (5-6 
months) and in the late plaque phase (14 months). As well as possessing 5-HT3 receptor 
antagonism and α7 nAChR partial agonism properties, tropisetron also binds to the 
ectodomain of APP, with a sub-micromolar affinity (13). Interestingly, direct comparisons 
of tropisetron with current AD therapeutic drugs such as, memantine and donepezil, revealed 
that tropisetron induced greater improvements in memory and the sAPPα/Aβ1-42 ratio (13). 
Furthermore, it is reported that tropisetron protects against Aβ-induced neurotoxicity in vivo, 
through both 5-HT3 receptor-dependent and independent pathways (14).  
4. Role of α7 nAChR in inflammation 
Positron emission tomography (PET) studies using [11C]PIB (Pittsburgh Compound-B) and 
[11C](R)-PK11195 (an antagonist at the mitochondrial 18 kDa translocator protein) 
demonstrated that Aβ deposition and microglial activation could be detected in the brain of 
patients with amnestic MCI (15, 16). Longitudinal studies suggested that MCI subjects with 
high PIB retention are much more likely to convert to AD than subjects with low PIB 
retention (16), indicating that Aβ - PET may play a prognostic role in the clinical evaluation 
of MCI. Most significantly, longitudinal studies showed that cognitively normal subjects with 
elevated PIB were at much higher risk for longitudinal cognitive decline and the emergence of 
clinically significant cognitive impairment, relative to PIB negative, age- and education- 
matched subjects (16). In addition, the AD Neuroimaging Initiative research suggests that AD 
begins with Aβ accumulation and inflammation in the brain, which ultimately leads to 
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synaptic dysfunction, neurogeneration, and cognitive or functional decline, although 
inflammation is not always detrimental in the AD pathological process (Figure 1 and 2)(16).  
In 2003, Wang et al. (17) reported on the key role of α7 nAChR in the inflammatory 
process. They found that the anti-inflammatory action of vagal stimulation worked in 
wild-type, but not α7 nAChR knock-out mice (17). This led to the proposal of a “cholinergic 
anti-inflammatory pathway” (18). Preclinical models have provided a plethora of evidence 
supporting a beneficial effect for activation or mimicry of the “cholinergic anti-inflammatory 
pathway” in a number of disorders (e.g., inflammatory bowel disease, postoperative and 
endotoxin-induced ileus) (18). Interestingly, a report showed that tropisetron can attenuate 
serum levels of the pro-inflammatory cytokine, interleukin-6 (IL-6), in rats after cecal ligation 
and puncture (19), indicating a potent anti-inflammatory effect for tropisetron. It is also 
known that 5-HT3 receptor antagonists, including tropisetron, conferred anti-inflammatory 
properties. Considering the crucial role of α7 nAChR on Aβ deposition and inflammation in 
the brain, tropisetron may act to prevent or delay the onset of Alzheimer’s disease from the 
state of MCI (Figure 1 and Figure 2). 
5. Encenicline (EVP-6124) 
EnVivo Pharmaceuticals Inc. (now Forum Pharmaceuticals, Inc.) reported results for a Phase 
2b trial of encenicline hydrochloride (EVP-6124; 0.3, 1 or 2 mg, 23-weeks), another α7 
nAChR partial agonist, in patients (n=409) with mild to moderate AD (20). Encenicline (2 
mg) showed statistically significant effects on a number of cognitive and clinical endpoints, 
including the primary endpoint of AD Assessment Scale-Cognitive Subscale (ADAS-Cog) 
status. The drug was safe and well tolerated, showing predominantly mild treatment-emergent 
adverse effects (1 mg = 48.5%, 2 mg = 53%). Next, the company initiated COGNITIV AD, a 
Phase 3 clinical trial program, using encenicline in mild to moderate AD. The program 
consists of two randomized, double-blind, placebo-controlled trials, enrolling approximately 
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1,600 patients at sites in the U.S. and other countries worldwide (20).  
6.  Conclusion 
As mentioned above, tropisetron interacts with both the 5-HT3 receptor and α7 nAChR, as 
well as interfacing directly with APP, targets that are all associated with early AD pathology 
(Figure 2). This makes tropisetron an attractive potential therapeutic drug to delay or prevent 
MCI and AD, particularly since current medications do not affect the underlying disease 
process. Further clinical studies are needed to fully evaluate the efficacy of tropisetron in AD 
prevention. 
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Expert Opinion 
Alzheimer’s disease (AD) is the most common cause of dementia in the elderly, with a 
worldwide prevalence estimated to quadruple over the next 50 years. It is a slowly 
progressing disease, characterized by three stages; an early preclinical stage with no 
symptoms, a middle stage with mild cognitive impairment (MCI) and a final stage with 
dementia. However, no effective treatment is available to slow down or stop the onset of MCI 
or AD.  
     A prominent feature of AD pathology is the loss of cholinergic neurons and nicotinic 
acetylcholine receptors (nAChRs) throughout the brain (Figure 1). Given the role of the 
amyloid-β (Aβ) - α7 nAChR interaction in AD pathology, both Aβ and α7 nAChR are valid 
therapeutic targets for AD. A number of PET studies demonstrated the presence of Aβ 
depositions in the brain, some 10 to 20 years before dementia or even MCI is diagnosed 
(Figure 1). A recent preclinical study showed that in addition to interaction with both the 
5-HT3 receptor and α7 nAChR, tropisetron interacts directly with APP, targets that are all 
associated with early AD pathology (13). Interestingly, direct comparisons of tropisetron with 
current AD therapeutic drugs (e.g., memantine and donepezil), revealed greater improvement 
in memory and sAPPα/Aβ1-42 ratios with tropisetron (13). In addition, tropisetron showed 
excellent oral bioavailability, brain penetration, cognitive effects and biomarker effects at 
currently used human equivalent doses (13). 
Taken together, current evidence highlights tropisetron as a promising therapeutic drug 
to delay or prevent MCI and mild to moderate AD, especially since it already has worldwide 
approval for clinical use in a different disorder (Figure 1 and Figure 2). Future studies using 
a combination of tropisetron and other drugs, such as β-site APP cleaving enzyme (BACE1) 
inhibitors will be interesting. 
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Figure legends: 
Figure 1. The life course in healthy aging, MCI subjects and AD patients  
As people grow older, healthy subjects develop age-related memory loss. 
Subjects with mild cognitive impairment (MCI) develop a greater degree of 
memory problems relative to age-matched healthy subjects, although they do 
not experience the personality changes or other problems characteristic of AD. 
Studies using PET showed that amyloid-β (Aβ) deposition and inflammation 
are present in the brains of MCI subjects. AD patients suffer severe memory 
loss, Aβ deposition, inflammation and loss of cholinergic neurons and α7 
nAChRs. The deposition of Aβ in the brain starts before MCI, and increases 
with age. Therefore, tropisetron could potentially prevent the onset of AD if 
administered during or before the onset of MCI.  
Figure 2. Schematic diagram of the proteolytic events and cleave products 
associated with APP and possible mechanistic action of tropisetron in the 
prevention of AD 
Amyloid precursor protein (APP) is metabolized by a membrane-associated 
protease, α-secretase, and this cleavage releases the extracellular 
amino-terminal ectodomain of APP (APPSα), which displays trophic 
properties. The alternative cleavage pathway involves two sequential cleavages 
by β- and γ-secretase and gives rise to a series of amyloid-β (Aβ). 
Accumulating evidence suggests that interaction between Aβ peptides and α7 
nAChRs is integral to the pathology of AD. The interaction between Aβ 
peptides and α7 nAChRs might induce Aβ deposition and inflammation in the 
brain, resulting in the loss of cholinergic neurons and α7 nAChR. These 
neurotoxic events may promote cognitive decline, followed by MCI, and 
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ultimately lead to AD. In combination with an α7 nAChR agonist and 
serotonin 5-HT3 receptor antagonist, tropisetron, binds to APP, with a 
sub-micromolar affinity. The interaction of tropisetron with 5-HT3 receptors 
also plays a role in the anti-inflammatory and neuroprotective effect against 
Aβ-induced neurotoxicity. Taken together, tropisetron could act as a potential 
therapeutic drug for AD, if be administered during the period of MCI or early 
stages of AD. 
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